EE200200550A - Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine - Google Patents
Karbamaatsed kaspaasi inhibiitorid ja nende kasutamineInfo
- Publication number
- EE200200550A EE200200550A EEP200200550A EEP200200550A EE200200550A EE 200200550 A EE200200550 A EE 200200550A EE P200200550 A EEP200200550 A EE P200200550A EE P200200550 A EEP200200550 A EE P200200550A EE 200200550 A EE200200550 A EE 200200550A
- Authority
- EE
- Estonia
- Prior art keywords
- caspase inhibitors
- carbamate
- carbamate caspase
- inhibitors
- caspase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/30—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with acyl radicals attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19282600P | 2000-03-29 | 2000-03-29 | |
PCT/US2001/010182 WO2001072707A2 (en) | 2000-03-29 | 2001-03-29 | Carbamate caspase inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200200550A true EE200200550A (et) | 2004-02-16 |
Family
ID=22711181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200550A EE200200550A (et) | 2000-03-29 | 2001-03-29 | Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine |
Country Status (32)
Country | Link |
---|---|
US (2) | US6689784B2 (et) |
EP (1) | EP1268425B1 (et) |
JP (2) | JP4298200B2 (et) |
KR (1) | KR100858640B1 (et) |
CN (2) | CN1994298A (et) |
AR (1) | AR027993A1 (et) |
AT (1) | ATE384695T1 (et) |
AU (2) | AU2001249619B2 (et) |
BG (1) | BG107136A (et) |
BR (1) | BR0109588A (et) |
CA (1) | CA2403959A1 (et) |
CZ (1) | CZ20023227A3 (et) |
DE (1) | DE60132567T2 (et) |
DK (1) | DK1268425T3 (et) |
EA (1) | EA005740B1 (et) |
EE (1) | EE200200550A (et) |
ES (1) | ES2296742T3 (et) |
HK (1) | HK1052355B (et) |
HR (1) | HRP20020782A2 (et) |
HU (1) | HUP0301472A3 (et) |
IL (2) | IL151829A0 (et) |
MX (1) | MXPA02009633A (et) |
NO (1) | NO325062B1 (et) |
NZ (1) | NZ521639A (et) |
PE (1) | PE20011267A1 (et) |
PL (1) | PL201081B1 (et) |
PT (1) | PT1268425E (et) |
SK (1) | SK13922002A3 (et) |
TW (1) | TWI318207B (et) |
WO (1) | WO2001072707A2 (et) |
YU (1) | YU73702A (et) |
ZA (1) | ZA200207483B (et) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541237A (ja) | 1999-04-09 | 2002-12-03 | サイトビア インコーポレイテッド | カスパーゼインヒビターおよびその使用 |
ATE409688T1 (de) | 1999-08-27 | 2008-10-15 | Cytovia Inc | Substituierte alpha-hydroxy-säuren als caspase- hemmer und ihre verwendung |
CN1994298A (zh) * | 2000-03-29 | 2007-07-11 | 沃泰克斯药物股份有限公司 | 氨基甲酸酯天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途 |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
US20040192889A1 (en) * | 2001-03-30 | 2004-09-30 | Dale Bredesen | Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
US7351702B2 (en) | 2001-05-23 | 2008-04-01 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
US7410956B2 (en) | 2002-02-11 | 2008-08-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
EP1499898A2 (en) * | 2002-04-19 | 2005-01-26 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
EP1447093A1 (en) * | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
EP1607101A4 (en) * | 2003-02-24 | 2007-10-24 | Daiichi Seiyaku Co | INHIBITOR OF DEGRADATION OF PROTEIN INTERACTING WITH HEPATITIS B VIRUS PROTEIN X |
AU2003902704A0 (en) * | 2003-05-29 | 2003-06-19 | Crc For Waste Management And Pollution Control Limited Of Unsw | Process for producing a nanoscale zero-valent metal |
JP4898658B2 (ja) * | 2004-03-12 | 2012-03-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | アスパラギン酸アセタールカスパーゼ阻害剤の製造のための方法および中間体 |
US7544855B2 (en) * | 2004-04-23 | 2009-06-09 | Buck Institute | Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664 |
CN1980648A (zh) * | 2004-05-15 | 2007-06-13 | 沃泰克斯药物股份有限公司 | 使用ice抑制剂治疗癫痫发作 |
KR100619440B1 (ko) | 2004-05-20 | 2006-09-08 | 한기종 | 포름아마이드 유도체 제조방법 |
KR100619439B1 (ko) | 2004-05-27 | 2006-09-08 | 한기종 | 포밀기 도입된 아민유도체의 제조방법 |
CN1980658A (zh) * | 2004-05-27 | 2007-06-13 | 沃泰克斯药物股份有限公司 | 治疗自身炎性疾病的ice抑制剂 |
US8012751B2 (en) * | 2005-03-31 | 2011-09-06 | Wisconsin Alumni Research Foundation | Differentiation of pluripotent embryonic stem cells |
ZA200801172B (en) * | 2005-07-28 | 2009-04-29 | Vertex Pharma | Caspase inhibitor prodrugs |
JP4976304B2 (ja) * | 2005-10-07 | 2012-07-18 | パナソニック株式会社 | 音響信号処理装置、音響信号処理方法およびプログラム |
WO2008051243A2 (en) | 2005-11-30 | 2008-05-02 | Massachusetts Institute Of Technology | Pathogen-detecting cell preservation systems |
EP2012801A4 (en) * | 2006-04-24 | 2009-08-05 | Gloucester Pharmaceuticals Inc | GEMCITABINE COMBINATION THERAPY |
EP2043672A4 (en) * | 2006-07-07 | 2009-10-21 | Univ Leland Stanford Junior | SELECTIVE CASPASE INHIBITORS |
WO2008021745A2 (en) * | 2006-08-16 | 2008-02-21 | Itherx Pharmaceuticals, Inc. | Hepatitis c virus entry inhibitors |
EP2054076A2 (en) * | 2006-08-21 | 2009-05-06 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
WO2008137567A1 (en) * | 2007-05-01 | 2008-11-13 | Cedars-Sinai Medical Center | Caspase inhibitors in the treatment of infection-associated preterm delivery |
KR101009588B1 (ko) * | 2008-06-04 | 2011-01-20 | 거진산업주식회사 | 미세여과막을 이용한 부유고형물 처리장치 |
JP2012051804A (ja) * | 2008-12-26 | 2012-03-15 | Kyoto Univ | Eg5阻害剤 |
KR101010350B1 (ko) * | 2009-03-26 | 2011-01-25 | 삼성중공업 주식회사 | 역세척 여과장치 |
JP5980790B2 (ja) | 2010-11-05 | 2016-08-31 | ブランダイス ユニバーシティBrandeis University | バイオマーカーとしての、ice切断されたアルファ−シヌクレイン |
TW201236239A (en) | 2010-11-16 | 2012-09-01 | Solvay | Rechargeable metal or metal-ion cell |
EP2490021A1 (en) | 2011-02-18 | 2012-08-22 | Biotempt B.V. | Modulators of PRR and GPCR signalling |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
KR20170015312A (ko) | 2014-05-12 | 2017-02-08 | 코나터스 파마슈티칼스, 인크. | 카스파제 억제제를 사용한 만성 간질환의 합병증의 치료 |
WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
AU2016381974A1 (en) | 2015-12-31 | 2018-07-12 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
CA3039283A1 (en) | 2016-10-05 | 2018-04-12 | Novartis Ag | Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
WO2018216012A1 (en) * | 2017-05-24 | 2018-11-29 | Ramot At Tel-Aviv University Ltd. | Chemiluminescent probes for imaging/detection of proteases |
WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015577A1 (en) | 1990-04-04 | 1991-10-17 | Black, Roy, A. | INTERLEUKIN 1'beta' PROTEASE |
ATE257517T1 (de) | 1991-08-30 | 2004-01-15 | Vertex Pharma | Interleukin 1-beta protease und ihre inhibitoren |
EP0618223A3 (en) | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents. |
US6162828A (en) | 1995-03-31 | 2000-12-19 | Takeda Chemical Industries, Ltd. | Cysteine protease inhibitor |
US6136834A (en) * | 1995-12-27 | 2000-10-24 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds and pharmaceutical agents containing such derivative |
NZ334605A (en) | 1996-09-12 | 2000-08-25 | Idun Pharmaceuticals Inc | C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases and for treatments of inflammatory, autoimmune, neurodegenerative disorders and in the prevention of ischemic injury |
JP2001506974A (ja) | 1996-10-11 | 2001-05-29 | ワーナー―ランバート・コンパニー | インターロイキン―1β変換酵素のアスパルテートエステル阻害剤 |
CA2268086A1 (en) * | 1996-10-11 | 1998-04-23 | Warner-Lambert Company | Sulfonamide interleukin-1.beta. converting enzyme inhibitors |
BR9814817A (pt) * | 1997-10-10 | 2002-01-08 | Cytovia Inc | Inibidores de apoptose de dipeptìdio e o uso dos mesmos |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
AU755273B2 (en) | 1998-03-16 | 2002-12-05 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
CN1346344A (zh) | 1999-03-16 | 2002-04-24 | 西托维亚公司 | 取代的2-氨基苯甲酰胺天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其应用 |
JP2002541237A (ja) | 1999-04-09 | 2002-12-03 | サイトビア インコーポレイテッド | カスパーゼインヒビターおよびその使用 |
ATE409688T1 (de) | 1999-08-27 | 2008-10-15 | Cytovia Inc | Substituierte alpha-hydroxy-säuren als caspase- hemmer und ihre verwendung |
CN1994298A (zh) * | 2000-03-29 | 2007-07-11 | 沃泰克斯药物股份有限公司 | 氨基甲酸酯天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途 |
-
2001
- 2001-03-29 CN CNA2006101685798A patent/CN1994298A/zh active Pending
- 2001-03-29 EA EA200201030A patent/EA005740B1/ru not_active IP Right Cessation
- 2001-03-29 DE DE60132567T patent/DE60132567T2/de not_active Expired - Lifetime
- 2001-03-29 AU AU2001249619A patent/AU2001249619B2/en not_active Ceased
- 2001-03-29 CZ CZ20023227A patent/CZ20023227A3/cs unknown
- 2001-03-29 AR ARP010101526A patent/AR027993A1/es active IP Right Grant
- 2001-03-29 EE EEP200200550A patent/EE200200550A/et unknown
- 2001-03-29 CN CNB018075789A patent/CN100358869C/zh not_active Expired - Fee Related
- 2001-03-29 TW TW090107500A patent/TWI318207B/zh not_active IP Right Cessation
- 2001-03-29 US US09/821,161 patent/US6689784B2/en not_active Expired - Fee Related
- 2001-03-29 DK DK01922868T patent/DK1268425T3/da active
- 2001-03-29 EP EP01922868A patent/EP1268425B1/en not_active Expired - Lifetime
- 2001-03-29 PL PL358430A patent/PL201081B1/pl not_active IP Right Cessation
- 2001-03-29 NZ NZ521639A patent/NZ521639A/en not_active IP Right Cessation
- 2001-03-29 WO PCT/US2001/010182 patent/WO2001072707A2/en active IP Right Grant
- 2001-03-29 AT AT01922868T patent/ATE384695T1/de active
- 2001-03-29 HU HU0301472A patent/HUP0301472A3/hu unknown
- 2001-03-29 KR KR1020027012780A patent/KR100858640B1/ko not_active IP Right Cessation
- 2001-03-29 BR BR0109588-9A patent/BR0109588A/pt not_active IP Right Cessation
- 2001-03-29 YU YU73702A patent/YU73702A/sh unknown
- 2001-03-29 PE PE2001000296A patent/PE20011267A1/es not_active Application Discontinuation
- 2001-03-29 JP JP2001570620A patent/JP4298200B2/ja not_active Expired - Fee Related
- 2001-03-29 CA CA002403959A patent/CA2403959A1/en not_active Abandoned
- 2001-03-29 MX MXPA02009633A patent/MXPA02009633A/es active IP Right Grant
- 2001-03-29 ES ES01922868T patent/ES2296742T3/es not_active Expired - Lifetime
- 2001-03-29 PT PT01922868T patent/PT1268425E/pt unknown
- 2001-03-29 IL IL15182901A patent/IL151829A0/xx unknown
- 2001-03-29 AU AU4961901A patent/AU4961901A/xx active Pending
- 2001-03-29 SK SK1392-2002A patent/SK13922002A3/sk unknown
-
2002
- 2002-09-18 ZA ZA200207483A patent/ZA200207483B/en unknown
- 2002-09-19 IL IL151829A patent/IL151829A/en not_active IP Right Cessation
- 2002-09-23 BG BG107136A patent/BG107136A/bg unknown
- 2002-09-27 HR HRP20020782 patent/HRP20020782A2/hr not_active Application Discontinuation
- 2002-09-27 NO NO20024661A patent/NO325062B1/no not_active IP Right Cessation
-
2003
- 2003-07-02 HK HK03104710.8A patent/HK1052355B/zh not_active IP Right Cessation
- 2003-08-21 US US10/645,043 patent/US7074782B2/en not_active Expired - Fee Related
-
2008
- 2008-06-11 JP JP2008153569A patent/JP2008266348A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200200550A (et) | Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine | |
NO20020343D0 (no) | Kaspase-inhibitorer og anvendelse derav | |
NO20022656D0 (no) | Caspaseinhibitorer og anvendelse derav | |
DK1122244T3 (da) | Uracilforbindelser og anvendelse deraf | |
DK1251848T3 (da) | Gyraseinhibitorer og anvendelse deraf | |
EE200200715A (et) | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena | |
DE50112013D1 (de) | Deodorantien und antiperspirantien | |
ID30590A (id) | Celana sekali pakai jenis-celana pendek | |
EE200100373A (et) | Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena | |
EE200200626A (et) | Antraniilamiidid ja nende kasutamine ravimitena | |
NO20024099D0 (no) | Lavdose entecavir-formulering og anvendelse | |
PT1326853E (pt) | Novos tiadiazoles e oxadiazoles e sua utilizacao como inibidores da fosfodiesterase-7 | |
DE60139763D1 (de) | Lanzen und -tieren | |
EE200300247A (et) | Isotiasool-4-karboksamiidi soolad ja nende kasutamine hüperproliferatsioonivastaste vahenditena | |
IS6822A (is) | Imidazól- og bezimidazól kaspasatálmar og notkun þeirra | |
NO20025510L (no) | Dibenzoazulen-derivater samt anvendelse derav | |
FI20001715A0 (fi) | Rankoihin liittyvät järjestelyt ja menetelmät | |
DE50104507D1 (de) | Reinigungs- und desinfektionsmittel | |
DE60117096D1 (de) | Dihydroindol- und tetrahydrochinolinderivate | |
NO20024617D0 (no) | Aryl- og heteroarylsulfonater | |
PT1267621E (pt) | Composicoes e metodos herbicidas sinergeticos | |
NO20025135L (no) | Antihypertensive midler og anvendelse | |
SE0002629D0 (sv) | Novel compounds and their use | |
SI1268425T1 (sl) | Zaviralci karbamat kaspaze in uporaba le-teh | |
FIU20000507U0 (fi) | Clinikit DiagnoPacks ja Openkit-konsepti |